Trial Profile
A Phase I Trial of Venetoclax (ABT-199) and Dexamethasone for Relapsed or Refractory Systemic AL Amyloidosis
Status:
Discontinued
Phase of Trial:
Phase I
Latest Information Update: 05 Nov 2021
Price :
$35
*
At a glance
- Drugs Dexamethasone (Primary) ; Venetoclax (Primary)
- Indications Amyloid light-chain amyloidosis
- Focus Adverse reactions
- 19 Aug 2020 Status changed from suspended to discontinued.
- 01 May 2019 Planned primary completion date changed from 1 Jan 2019 to 1 Jan 2020.
- 01 May 2019 Status changed from recruiting to suspended.